Allergen Immunotherapy for the Control of Allergic Rhinoconjunctivitis
DOI:
https://doi.org/10.58931/cait.2021.1324Abstract
Allergen immunotherapy (AIT) has been available for over 100 years as a unique method of treating various allergic conditions, most efficaciously allergic rhinitis/ rhinoconjunctivitis, allergic asthma and venom allergy. First developed by Noon et al in 1911, this therapy is an attractive option for patients suffering from these chronic conditions due to its potential for disease-modification. As opposed to avoidance measures and other pharmacotherapies, patients on immunotherapy can, in some cases, achieve long-term benefits after 3–5 years of treatment due to the induction of allergen tolerance. This article will focus primarily on patients with allergic rhinitis/rhinoconjunctivitis.
References
Durham SR. Allergen immunotherapy: 100 years on. Clin Exp Allergy. 2011 Sep;41(9):1171. doi:10.1111/j.1365-2222.2009.03843.x
Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Nobel W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999 Aug 12;341(7): 468-475. doi:10.1056/NEJM199908123410702
Penagos M, Durham SR. Duration of allergen immunotherapy for inhalant allergy. Curr Opin Allergy Clin Immunol. 2019 Dec;19(6): 594-605. doi:10.1097/ACI.0000000000000585
Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on Allergen Immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019 May;74(5): 855-873. doi:10.1111/all.13749
Roberts G, Pfaar O, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018 Apr;73(4):765-798. doi:10.1111/all.13317
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-S55. doi:10.1016/j.jaci.2010.09.034
Shamji MH, Layhadi JA, Sharif H, et al. Immunological responses and biomarkers for allergen specific immunotherapy against inhaled allergens. J Allergy Clin Immunol Pract. 2021 May;9(5):1769-1778. doi:10.1016/j.jaip.2021.03.029
Grastek Product Monograph; ALK-Abello A/S; Date of Revision: March 17, 2017.
Oralair Product Monograph; Stallergens Canada Inc.; Date of Revision: Sept 2016.
Ragwitek Product Monograph; ALK-Abello A/S; Date of Revision: March 17, 2017.
Acarizax Product Monograph; ALK-Abello A/S; Date of Revision: April 25, 2017.
Itulatek Product Monograph; ALK-Abello A/S; Date of Revision: March 17, 2017.
Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 1991 Jul;88(1):27-32. doi:10.1016/0091-6749(91)90297-2
Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004 Mar 1;172(5):3252-3259. doi:10.4049/jimmunol.172.5.3252
Wilson DR, Nouri-Aria KT, Walker SM et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 2001 Jun;107(6):971-976. doi:10.1067/mai.2001.115483
Shamji MH, Layhadi JA, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy. J Allergy Clin Immunol. 2019 Mar;143(3):1131-1142.e4. doi:10.1016/j.jaci.2018.06.041
Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007 Sep;120(3):707-713. doi:10.1016/j.jaci.2007.06.013
Radulovic S, Jacobson MR, Durham SR, et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008 Jun;121(6):1467-1472.e1. doi:10.1016/j.jaci.2008.03.013
O’Hehir RE, Gardner LM, De Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med. 2009 Nov 15;180(10):936-47. doi:10.1164/rccm.200905-0686OC
Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010 Apr;40(4):598-606. doi:10.1111/j.1365-2222.2010.03462.x
Sharif H, Acharya S, Dhandalay GKR, Varricchi G, Krasner-Macleod S, Laisuan W, et al. Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. J Allergy Clin Immunol. 2021 Feb;147(2):663-676. doi:10.1016/j.jaci.2020.10.035
Wambre E. Effect of allergen-specific immunotherapy on CD4+ T cells. Curr Opin Allergy Clin Immunol. 2015 Dec;15(6): 581-587. doi:10.1097/ACI.0000000000000216
Wambre E, DeLong JH, James EA, et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol. 2012 Feb; 129: 544-551.e1-551.e1-7. doi:10.1016/j.jaci.2011.08.034
Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011 Jan;127(1):18-27. doi:10.1016/j.jaci.2010.11.030
Zissler UM, Jakwerth CA, Guerth FM, et al. Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT. EBioMedicine. 2018 Oct;36:475-488. doi:10.1016/j.ebiom.2018.09.016
van de Veen W. The role of regulatory B cells in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2017 Dec;17(6):447-452. doi:10.1097/ACI.0000000000000400
van de Veen W, Stanic B, Wirz OF, et al. Role of regulatory B cells in immune tolerance to allergens and beyond. J Allergy Clin Immunol. 2016 Sep;138(3): 654-665. doi:10.1016/j.jaci.2016.07.006
van de Veen W. Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013 Apr;131(4):1204-1212. doi:10.1016/j.jaci.2013.01.014
Boonpiyathad T, van de Veen W, Wirz O, et al. Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy. J Allergy Clin Immunol. 2019 Mar;143(3):1077-1086.e10. doi:10.1016/j.jaci.2018.10.061
Mjosberg JM, Trifari S, Crellin NK et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011 Sep 11;12(11):1055-62. doi:10.1038/ni.2104
Nouri-Aria KT, Wachholz PA, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004;172:3252-3259
Ljorring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67:217-226.
Gleich GJ, Zimmermann EM, et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982;70:261-271.
Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121:512-518.
Di Lorenzo G, Mansueto P, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009; 23(10.e1-10.e4):1103-1110.
Yonekura S, Horiguchi S, et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol. 2011;139:65-74.
Jutel M, Jaeger L, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608-613.
Reisinger J, Horak F, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005;116:347-354.
Dhami S, Nurmatov U, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72:1597-1631.
Calderon MA, Bacharier LB. Controversies in Allergy: A Pro/Con Review of Sublingual Allergen Immunotherapy and Allergic Asthma. J Allergy Clin Immunol Pract. 2021;9(5):1818-1825.
Bergmann KC, Demoly P, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2013;133:1608-1614.
Durham SR, Emminger W, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717-725.
Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64:1394-1401.
Eng PA, Borer-Reinhold M, et al. Twelve year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61(2):198-201.
Kristiansen M, Dhami S, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28:18-29.
Gradman J, Halken S, et al. Preventative effect of allergen immunotherapy on asthma and new sensitizations. JACI: In Practice. 2021;9(2):1813-1817.
Scadding GW, Calderon MA, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317:615-625.
Möller C, Dreborg S, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251-256.
Niggemann B, Jacobsen L, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61:855-859.
Jacobsen L, Niggemann B, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943-948.
Valovirta E, Petersen TH, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141:529-538.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72:691-704.
Calderon MA, Vidal C, et al. On behalf of the EASSI Doctors’ Group. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. Allergy. 2017;72:462-472.
Rodríguez del Río P, Vidal C, et al. The European survey on adverse systemic reactions in allergen immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol. 2017;28:60-70.
Calderon MA, Simons FE, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302-311.
Canonica GW, Cox L, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021-1035.
Robertson K, Montazeri N, Shelke U, Jeimy S, Kim H. A single centre retrospective study of systemic reactions to subcutaneous immunotherapy. Allergy Asthma Clin Immunol. 2020;16(93). doi:10.1186/s13223-020-00491-5
Pfaar O, Creticos PS, et al. One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. J Allergy Clin Immunol Pract. 2021;9(5):1791-1803.
